Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Rovalpituzumab tesirine

EU orphan designation number: EU/3/16/1667   
Active ingredient: Rovalpituzumab tesirine
Indication: Treatment of small cell lung cancer
Sponsor: AbbVie Ltd
Abbvie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4UB, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
01/06/2016 Orphan designation EMA/OD/015/16 (2016)3423 of 30/05/2016
08/07/2016 Corrigendum (2016)3423 of 30/05/2016
09/02/2017 Transfer of orphan designation EMA/OD/015/16 (2017)1048 of 08/02/2017